IDL Diagnostics AB (IDLDX)

medical devices

About

IDL Diagnostics AB is a Swedish in vitro diagnostics (IVD) company based in Stockholm, founded in 2000. The company specializes in developing, manufacturing, and selling diagnostic tests for oncological and bacterial diseases. Its mission is to enhance disease monitoring and provide valuable information to healthcare decision-makers. The product portfolio includes the UBC Rapid test for bladder cancer diagnosis and monitoring, the AroCell TK 210 ELISA biomarker test for tracking therapy response in various cancers, and the TUBEX TF test for detecting acute typhoid fever. IDL Diagnostics also licenses tumor marker technologies to strategic partners to broaden its offerings and market presence. Publicly traded on the Nasdaq Stockholm under the ticker IDLDX, IDL Diagnostics employs around 20 people and is led by CEO Anders Hultman. The company primarily serves clinical customers such as hospitals and laboratories, focusing on cancer and infectious disease diagnostics.

Technologies

Outlook Microsoft Office 365 Google Cloud Hosting WordPress.org Mobile Friendly Nginx Google Font API Google Tag Manager Wistia

Keywords

medical equipment manufacturing biomarker assays biomarker development healthcare improvement diagnostics portfolio typhoid tubex tf clinical diagnostics diagnostic product portfolio diagnostic innovation disease management medical devices medical research biotechnology cancer biomarker tests high-value clinical information urine-based biomarkers thymidine kinase 1 tk 210 elisa cost-efficient diagnostics oncological diseases clinical validation medical equipment and supplies manufacturing diagnostic technology non-invasive tests oncology diagnostics point-of-care testing medical diagnostics disease monitoring automated platforms diagnostic solutions automated elisa platforms

Location

39 Karlsbodavaegen, Stockholm, Stockholm County, Sweden, 168 67

Related Companies

Companies in the same industry